Answers are grounded in this paper and cite their sources.
Background: Tuberculosis (TB) is an infectious, contagious, and fatal disease, according to the 2025 Global Tuberculosis Report of the World Health Organization (WHO). Phosphopantetheinyl transferase (PptT) is an enzyme that acts as a catalyst in the biosynthesis of cellular lipids in Mycobacterium tuberculosis. It is considered potential target for the development of anti-tuberculosis drugs. Methods: We used molecular docking to establish a quantitative structure-activity relationship (QSAR) model for 25 amidinourea derivatives inhibitors of PptT. The binding free energies, a key physical descriptor, enabled us to elucidate the thermodynamic factors governing the interaction between the enzyme and the inhibitor. This approach, which combines structure-based molecular docking with quantitative modeling, identified specific, critical chemical substituents. This, in turn, led to the development of new derivatives that exhibit potent antitubercular activity. Results: The resulting QSAR model that accounts for 87% of the variation in biological activity, based on the binding free energies (BFE/PBSA) of the analogues used. Subsequently, an intuitive fragment-replacement approach, based on per-residue interaction energy, which indicates stabilizing interactions, was implemented to identify new analogues. Moreover, 200-ns molecular dynamics simulations have evaluated with satisfaction, the temporal evolution of various properties of the bound inhibitors, such as root mean square deviation (RMSD) from the initial conformation, radius of gyration (rGyr), number of intramolecular hydrogen bonds (intraHB), molecular surface area (molSA), solvent-accessible surface area (SASA), and polar surface area (PSA). The BFE/GBSA of the three best analogs, calculated over the last 50 nanoseconds of the trajectory, align with BFE/PBSA values. Finally, favorable values for the pharmacokinetic descriptors of the best analogues are obtained using the QikProp, pkCSM, and mycoCSM programs. Conclusion: This study enabled us to identify a new amidinourea analogue AU_1-3-7-9, which is 10 times more active. Peer Review History: Received 22 July 2026; Reviewed 3 September 2026; Accepted 8 October; Available online 15 November 2026 Academic Editor: Prof. Dr. Gorkem Dulger, Duzce University, Turkey, gorkemdulger@yandex.com Reviewers: Dr. Sarfaraz Ahmed, Global Institute of Pharmaceutical Education and Research, Kashipur, Uttarakhand, India, sarfarazahmed1@gmail.com Sheima Nadim Kadhim, Deparment of Pharmacology and Toxicology, College of pharmacy, University of Basra, Iraq. ph.sheimanadim@yahoo.com
No takes yet. Share an insight, caveat, or question.
Kouakou et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: